UroGen Pharma (URGN) Misses Q4 EPS by 6c

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.84 million versus the consensus estimate of $41.45 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• L3Harris CEO steps down amid conduct review, shares drop
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30